Looking for the Patient Access ‘2020’ Conference?

With continued uncertainty for venues, live events and conferences due to COVID-19, we have decided to postpose the 2020 Patient Access conference to 2021. We are currently working with all the speakers to bring you the full programme as published below on Wednesday 22nd September 2021. Please register now and we will keep you updated.


A must-attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.

Our conference has been designed around three core market access areas, each with a specific mission to bring you the latest insights and information for accelerating patient access.

Developments in strategy and HTA

  • The importance of patient engagement throughout the HTA process
  • Using patient registries in HTAs
  • Appraisal process of medical devices compared with drugs
  • Health economic modelling of digital apps
  • Access to Orphan Medicines: Developing policies for the future

Innovation tools

  • Approaches to utilising Real World Evidence (RWE)
  • Using analytics and big data to gain competitive advantage in Market Access
  • Collaborative working and horizon scanning
  • Harnessing digital systems and technology to find new levels of patient value

Pricing and policy

  • VPAS – what you need to know
  • Updates on The Commercial Framework
  • Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
  • The NHS Long Term Plan and what this actually means for pharma companies

Who should attend?

This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.

The job functions that will benefit most include:

  • Heads of Market Access
  • Country Managers
  • Health Economists
  • Commercial Directors
  • Marketing Directors
  • Managing Directors
  • Chief Executives
  • Medical Directors
  • Policy Officers/Executives
  • Policy Advisors

Speakers

Lindsay Weaver – CEO, Metabolic Support UK

The importance of patient engagement throughout the HTA process

David Gillen – Vice President international Medical Affairs, Vertex

Using patient registries in HTAs

Melinda Goodall – Associate Director, NICE

Andi Orlowski – Head of Business Intelligence, Imperial College Healthcare Partners

Approaches to utilising Real World Evidence (RWE)

David Watson – Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)

The Voluntary Scheme; what you need to know

Darren Spevick – Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group

Harnessing digital systems and technology to find new levels of patient value

Carla Deakin – Programme Director, Commercial & Managed Access, NICE

Sarah Walker – Senior Consultant Policy and Public Affairs, MAP BioPharma

Kate Learoyd – Campaign Manager, NSPKU – National Society for Phenylketonuria

Christian Hill – CEO, MAP BioPharma

Find out more and register here!